As prostate cancer progresses, it becomes increasingly aggressive and can metastasise. In this form, the tumor is difficult to treat, which is reflected in high mortality rates: Worldwide, the malignant disease of the prostate is the second most common cause of cancer death in men.
Updated: Vaxcyte surges on Phase 1/2 data for 31-valent pneumococcal vaccine
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
September 4, 2024